Abstract
Docetaxel is a second-generation taxane and is used clinically as an anti-neoplastic agent in cancer chemotherapy via an anti-mitotic mechanism. Its efficacy is limited to a narrow therapeutic window. Inappropriately high concentrations may cause erythema, fluid retention, nausea, diarrhea, and neutropenia. As a result, dosing recommendations have changed from high dosage loading every 3 weeks to lower dosage loading weekly. We describe a method that can be used for therapeutic drug monitoring of docetaxel levels using turbulent flow liquid chromatography electrospray tandem mass spectrometry (TFC-HPLC-ESI-MS/MS). The method is rapid, requiring only 6.3 min per analytical run following a simple protein crash. The method requires only 100 μL of serum. Concentrations of docetaxel were quantified by a calibration curve relating the peak-area ratio of docetaxel to a deuterated internal standard (docetaxel-D9). The method was linear from 7.8 to 1000 ng/mL, with imprecision ≤6.2 %.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Salminen E, Bergman M, Huhtala S, Ekholm E (1999) Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol 17:1127
Saloustros E, Georgoulias V (2008) Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 8:1207–1222
Gilbert DC, Parker C (2005) Docetaxel for the treatment of prostate cancer. Future Oncol 1:307–314
Burstein HJ, Manola J, Younger J et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212–1219
Clarke DSJ, Rivory LP (2012) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114
Marzinke MA, Breaud AR, Clarke W (2013) The development and clinical validation of a turbulent-flow liquid chromatography-tandem mass spectrometric method for the rapid quantitation of docetaxel in serum. Clin Chim Acta 417:12–18
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Crutchfield, C.A., Marzinke, M.A., Clarke, W.A. (2016). Quantification of Docetaxel in Serum Using Turbulent Flow Liquid Chromatography Electrospray Tandem Mass Spectrometry (TFC-HPLC-ESI-MS/MS). In: Garg, U. (eds) Clinical Applications of Mass Spectrometry in Drug Analysis. Methods in Molecular Biology, vol 1383. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3252-8_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3252-8_14
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3251-1
Online ISBN: 978-1-4939-3252-8
eBook Packages: Springer Protocols